Jacobio Pharmaceuticals Group Co (OTCPK:JBPHF) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Jacobio Pharmaceuticals Group Co had a gross margin of 92.47% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Jacobio Pharmaceuticals Group Co Gross Margin % Related Terms
Jacobio Pharmaceuticals Group Co Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jacobio Pharmaceuticals Group Co Gross Margin % Chart
JBPHF vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Jacobio Pharmaceuticals Group Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jacobio Pharmaceuticals Group Co Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jacobio Pharmaceuticals Group Co's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Jacobio Pharmaceuticals Group Co's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Jacobio Pharmaceuticals Group Co (JBPHF) has a Gross Margin % of 92.47% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Jacobio Pharmaceuticals Group Co and its competitors. This is 601% above median its historical median of 13.20. Over the past decade, Jacobio Pharmaceuticals Group Co's Gross Margin % has ranged from 5.04 to 98.89. According to the industry distribution chart, Jacobio Pharmaceuticals Group Co ranks #28 out of 737 companies in the Biotechnology industry, placing it in the top 3.8%.
Is Jacobio Pharmaceuticals Group Co's Gross Margin % too high?
Jacobio Pharmaceuticals Group Co's current Gross Margin % of 92.47% is 601% above median its 10-year median of 13.20. Over the past 10 years, this metric has ranged from a low of 5.04 to a high of 98.89. The Biotechnology industry median Gross Margin % is 60.92. Jacobio Pharmaceuticals Group Co's value of 92.47% is 51.8% above this industry median. Based on the distribution chart, Jacobio Pharmaceuticals Group Co ranks #28 out of 737 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Jacobio Pharmaceuticals Group Co has a GF Score™ of 54/100, reflecting its overall financial health beyond just this single metric.
How does Jacobio Pharmaceuticals Group Co's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Jacobio Pharmaceuticals Group Co ranks #28 out of 737 companies for Gross Margin %. This places Jacobio Pharmaceuticals Group Co in the top 4% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.92. Jacobio Pharmaceuticals Group Co's value of 92.47% is 51.8% above this benchmark. Historically, Jacobio Pharmaceuticals Group Co's own Gross Margin % has ranged from 5.04 to 98.89 over the past decade. While the company's 10-year median is 13.20 vs. the industry median of 60.92, Jacobio Pharmaceuticals Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.92, based on 737 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jacobio Pharmaceuticals Group Co's current Gross Margin % of 92.47% is 51.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Jacobio Pharmaceuticals Group Co and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jacobio Pharmaceuticals Group Co's current Gross Margin % is 92.47%, which is 601% above median its own 10-year median of 13.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jacobio Pharmaceuticals Group Co stock overvalued right now?
Jacobio Pharmaceuticals Group Co (JBPHF) has a current Gross Margin % of 92.47%. The stock's GF Value™ is $0.42, compared to a current price of $0.87 — trading 106.6% above its estimated fair value. The current Gross Margin % is 92.47%, which is 601% above median its 10-year median of 13.20 and 51.8% above the Biotechnology industry median of 60.92. Jacobio Pharmaceuticals Group Co's overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Jacobio Pharmaceuticals Group Co (JBPHF), the current Gross Margin % is 92.47% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jacobio Pharmaceuticals Group Co (JBPHF) Overvalued in 2026?
Based on GuruFocus' analysis, Jacobio Pharmaceuticals Group Co stock appears to be overvalued.
The current stock price of $0.87 is trading 106.6% above its estimated GF Value™ of $0.42.
Key valuation signals for JBPHF:
Gross Margin %: 92.47% (601% above median its 10-year median of 13.20)
GF Value™: $0.42 vs. price of $0.87 (106.6% above fair value)
Industry Position: 51.8% above the Biotechnology median (#28 of 737)
No single metric tells the full story. See the JBPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jacobio Pharmaceuticals Group Co Business Description
Jacobio Pharmaceuticals Group Co Ltd is a clinical-stage pharmaceutical company focusing on the in-house discovery and development of oncology therapies. The company is engaged in developing breakthrough cancer therapies for patients. The producst pipeline of the company includes KRAS G12C inhibitor, SHP2 inhibitor, Pan-KRAS inhibitor, KRAS G12D ADC JAB-BX600, Aurora Kinase A (AURKA) inhibitor, BET inhibitor, P53 Y220C mutant proteins, and others.
54GF Score
Get the complete analysis for JBPHF
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JBPHF has been successfully added to your 
